Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;92(2):181-184.
doi: 10.1007/s12098-024-05148-4. Epub 2024 May 27.

Heterogeneity and Hierarchy of Immune Response to Primary Immunization in HIV-Infected Children on HAART and the Impact of an Additional Dose of Vaccine

Affiliations

Heterogeneity and Hierarchy of Immune Response to Primary Immunization in HIV-Infected Children on HAART and the Impact of an Additional Dose of Vaccine

Sonia Mathew et al. Indian J Pediatr. 2025 Feb.

Abstract

The nature of vaccine response inferiority is not well studied in children living with HIV (CLHIV). The authors investigated Hepatitis B Virus (HBV) and Diphtheria/Pertussis/Tetanus toxoid (DPT) vaccination responses following primary immunization in CLHIV (n = 42) and healthy controls (HC) (n = 38) and the effect of an additional vaccine dose. Antibody responses, CD4 and HBV-specific T/B cells were analysed using CMIA/ELISA and flow-cytometry. CLHIV had significantly lower baseline median antibody titres for all vaccines than HC (p <0.02). Differential seroprotection rates observed in CLHIV were, 4.8% for pertussis; 9.5% for HBV; 26.2% for diphtheria and 66.7% for tetanus. WHO staging significantly influenced anti-HBs levels (p = 0.0095). HBsAg-specific CD4+T-cells were significantly higher in CLHIV than HC (p = 0.042). An additional vaccine dose (HBV and Tdap) conferred a higher protection rate for tetanus and diphtheria (p <0.040) in CLHIV. These findings suggest that CLHIV exhibit a hierarchy of vaccine responses affecting antibody levels and protection rate, which was rescued by administering additional vaccine dose.

Keywords: Children; HIV; Hepatitis B; India; Tdap; Vaccine.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of Interest: None.

Similar articles

References

    1. UNAIDS. Global HIV and AIDS Statistics - Factsheet. [Internet]. Available at: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_... .
    1. Mukherjee A, Shah N, Singh R, Vajpayee M, Kabra SK, Lodha R. Outcome of highly active antiretroviral therapy in HIV-infected Indian children. BMC Infect Dis. 2014;14:701. - DOI - PubMed - PMC
    1. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055–65. - DOI - PubMed - PMC
    1. Bruzzese E, Pagano F, Diana A, Punzi L, Guarino A. Protection of vaccine preventable diseases in a population of HIV-infected children: a 3 years prospective study. Vaccines. 2021;9:1331. - DOI - PubMed - PMC
    1. Pessoa SD, Miyamoto M, Ono E, Gouvêa AFTB, de Moraes-Pinto MI, Succi RCM. Persistence of vaccine immunity against hepatitis B virus and response to revaccination in vertically HIV-infected adolescents on HAART. Vaccine. 2010;28:1606–12. - DOI - PubMed

Substances

LinkOut - more resources